ASCO 2023 | ASCO 2023 highlights in breast cancer: NATALEE, monarchE, and PENELOPE-B

Elisa Agostinetto, MD, Institut Jules Bordet, Brussels, Belgium, provides an overview of groundbreaking trials in breast cancer presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including findings from the Phase II NATALEE trial (NCT03701334) of ribociclib plus endocrine therapy in patients with early breast cancer. Dr Agostinetto additionally highlights findings from the monarchE trial (NCT03155997) of abemaciclib, and the use of ctDNA in PENELOPE-B trial (NCT01864746), which assessed in palbociclib in HER2- breast cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.